Journal article
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells
CE Teh, H Peng, MX Luo, T Tan, M Trussart, LJ Howson, CC Chua, C Muttiah, F Brown, ME Ritchie, AH Wei, AW Roberts, VL Bryant, MA Anderson, GJ Lindeman, DCS Huang, R Thijssen, DHD Gray
Blood Advances | ELSEVIER | Published : 2023
Abstract
Venetoclax is an effective treatment for certain blood cancers, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, most patients relapse while on venetoclax and further treatment options are limited. Combining venetoclax with immunotherapies is an attractive approach; however, a detailed understanding of how venetoclax treatment impacts normal immune cells in patients is lacking. In this study, we performed deep profiling of peripheral blood (PB) cells from patients with CLL and AML before and after short-term treatment with venetoclax using mass cytometry (cytometry by time of flight) and found no impact on the concentrations of key T-cell subsets or their..
View full abstractGrants
Awarded by Breast Cancer Research Foundation
Funding Acknowledgements
This work was supported by grants and fellowships from the Australian National Health and Medical Research Council (NHMRC) fellowships (1089072) (C.E.T.), (1090236 and 1158024) (D.H.D.G.), (1078730 and 1175960) (G.J.L.), (1079560) (A.W.R.), and (1043149 and 1156024) (D.C.S.H.); Investigator grants (1177718) (M.-A.A.), (1174902) (A.W.R.), and (2007884) (L.J.H.); a Fulbright Australia-America Postdoctoral Fellowship (C.E.T.); Victorian Cancer Agency Fellowships (MCRF20026) (C.E.T.) and (ECRF21014) (R.T.); Sir Clive McPherson Family Research Fellowship (V.L.B.); Cancer Council of Victoria Grants-in-Aid (1146518 and 1102104) (D.H.D.G.); Perpetual Impact Philanthropy funding (C.E.T.); Australian NHRMC grants (2002618) (C.E.T.), (1016647, 1113577, 1016701, 1113133, and 1079560) (A.W.R. and D.C.S.H.), (1113133 and 1153049) (G.J.L.), (2013478) (D.C.S.H. and R.T.), and the Metcalf Family (A.H.W.); the Leukemia and Lymphoma Society, US, Specialized Center of Research grant (7015-18) (A.H.W., A.W.R., and D.C.S.H.); a Medical Research Future Fund grant (1141460) (A.H.W.); National Breast Cancer Foundation Australia (IIRS-19-004); Breast Cancer Research Foundation (BCRF-20-182) (G.J.L.); Rae Foundation (V.L.B.); Jack Brockhoff Foundation Early Career Research grant (JBF4847-2021) (L.J.H.); University of Melbourne Melbourne Research Scholarship and Melbourne International Fee Remission Scholarship (H.P.); and Investigator Initiated Study support from AbbVie and Genentech (Roche) for the breast cancer study (#ACTRN12615000702516) (G.J.L).